These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36682092)

  • 21. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
    BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3.
    Castle PE; Schiffman M; Wheeler CM; Wentzensen N; Gravitt PE
    Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1675-81. PubMed ID: 20615885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of partial genotyping with HPV16/18 for triage of HPV positive, cytology negative women in the COMPACT study.
    Hanley SJB; Fujita H; Aoyama-Kikawa S; Kasamo M; Torigoe T; Matsuno Y; Noriaki S;
    J Gynecol Oncol; 2021 Nov; 32(6):e86. PubMed ID: 34708593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical evaluation of primary human papillomavirus (HPV) testing with extended HPV genotyping triage for cervical cancer screening: A pooled analysis of individual patient data from nine population-based cervical cancer screening studies from China.
    Dun C; Yuan M; Zhao X; Hu S; Arbyn M; Zhao F
    Cancer Med; 2024 Jun; 13(11):e7316. PubMed ID: 38828559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing the performance of 2 human papillomavirus assays for a new use indication: a real-world evidence-based evaluation in the United States.
    Wheeler CM; Torrez-Martinez NE; Torres-Chavolla E; Parvu V; Andrews JC; Du R; Robertson M; Joste NE; Cuzick J;
    Am J Obstet Gynecol; 2024 Feb; 230(2):243.e1-243.e11. PubMed ID: 37806613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk stratification for cervical precancer and cancer by DH3-HPV partial genotyping and cytology in women attending cervical screening: A retrospective cohort study.
    Fu Y; Li Y; Li X; Wang X; Lü W
    J Med Virol; 2023 Feb; 95(2):e28482. PubMed ID: 36609841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotyping and Cytology Triage of High-Risk HPV DNA Positive Women for Detection of Cervical High-Grade Lesions.
    El-Zein M; Bouten S; Abdrabo LS; Siblini A; Louvanto K; Franco E; Ferenczy A
    J Low Genit Tract Dis; 2023 Jan; 27(1):12-18. PubMed ID: 36205321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology.
    Stoler MH; Wright TC; Parvu V; Yanson K; Eckert K; Kodsi S; Cooper C
    Am J Clin Pathol; 2019 Mar; 151(4):433-442. PubMed ID: 30649177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
    Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
    Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing the time dependence of prognostic values of cytology and human papillomavirus testing in cervical cancer screening.
    Isidean SD; Wang Y; Mayrand MH; Ratnam S; Coutlée F; Franco EL; Abrahamowicz M;
    Int J Cancer; 2019 May; 144(10):2408-2418. PubMed ID: 30411802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HPV genotyping for triage of women with abnormal cervical cancer screening results: a multicenter prospective study.
    Nakamura Y; Matsumoto K; Satoh T; Nishide K; Nozue A; Shimabukuro K; Endo S; Nagai K; Oki A; Ochi H; Morishita Y; Noguchi M; Yoshikawa H
    Int J Clin Oncol; 2015 Oct; 20(5):974-81. PubMed ID: 25652908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.
    Agorastos T; Chatzistamatiou K; Katsamagkas T; Koliopoulos G; Daponte A; Constantinidis T; Constantinidis TC;
    PLoS One; 2015; 10(3):e0119755. PubMed ID: 25793281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cohort study of cervical screening using partial HPV typing and cytology triage.
    Schiffman M; Hyun N; Raine-Bennett TR; Katki H; Fetterman B; Gage JC; Cheung LC; Befano B; Poitras N; Lorey T; Castle PE; Wentzensen N
    Int J Cancer; 2016 Dec; 139(11):2606-15. PubMed ID: 27509172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of HPV-positive triage strategies combining extended genotyping with cytology or p16/ki67 dual staining in the Italian NTCC2 study.
    Benevolo M; Ronco G; Mancuso P; Carozzi F; De Marco L; Allia E; Bisanzi S; Rizzolo R; Gustinucci D; Del Mistro A; Frayle H; Confortini M; Viti J; Iossa A; Cesarini E; Bulletti S; Passamonti B; Gori S; Toniolo L; Bonvicini L; Venturelli F; Wentzensen N; Giorgi Rossi P;
    EBioMedicine; 2024 Jun; 104():105149. PubMed ID: 38759278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic value of high-risk HPV other than type 16/18 in high-grade cervical neoplasia among cytology-negative women: A multicenter retrospective study.
    Bai A; Xue P; Li Q; Jiang Y; Qiao Y
    Cancer Med; 2023 Jul; 12(13):14794-14805. PubMed ID: 37199394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Performance of combined liquid based cytology and HPV nucleic acid test for detecting cervical precancer among women attending screening].
    Jiang MY; Feng RM; Wang L; Li TY; Zhang AA; Cui JF; Pan QJ; Zhang X; Liu ML; Gao F; Chen W; Qiao YL
    Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):750-756. PubMed ID: 30392339
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
    Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
    JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
    Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
    J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Machine Learning Interpretation of Extended Human Papillomavirus Genotyping by Onclarity in an Asian Cervical Cancer Screening Population.
    Wong OGW; Ng IFY; Tsun OKL; Pang HH; Ip PPC; Cheung ANY
    J Clin Microbiol; 2019 Dec; 57(12):. PubMed ID: 31511337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.